Our latest market review found migraine therapy costs increased 21.7% year over year, while claims rose 10.8%, highlighting the impact of newer, high-cost CGRP therapies on plan sponsors. While innovative treatments are expanding options for patients, balancing access, clinical outcomes, and affordability remains critical.
At ProAct, we help clients navigate evolving therapeutic categories through evidence-based formulary management, utilization strategies, and clinical programs designed to optimize outcomes while controlling costs.
As the migraine landscape continues to evolve, thoughtful benefit design has never been more important.
